Claude Le Pen | Academic Influence

Claude Le Pen's AcademicInfluence.com Rankings

Claude Le Pen

Economics

#1334

World Rank

#1543

Historical Rank

economics Degrees

Download Badge

Economics

Claude Le Pen's Degrees

PhD Economics Université Paris Cité
Masters Economics Université Paris Cité
Bachelors Economics Université Paris Cité

Similar Degrees You Can Earn

Why Is Claude Le Pen Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Claude Le Pen was a French economist. He specialized in health economics. Biography Le Pen earned a doctorate in economics in 1980. He was a professor first at University of Rennes from 1981 to 1984, then at the Paris Dauphine University.

(See a Problem?)

Claude Le Pen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Systems medicine and integrated care to combat chronic noncommunicable diseases (2011) (230)
The economic cost of obesity: the French situation. (1995) (179)
"Specific" scale compared with "generic" scale: a double measurement of the quality of life in a French community sample of obese subjects. (1998) (168)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey (2005) (163)
Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). (2006) (123)
Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease (2006) (116)
Financial cost of osteoarthritis in France. The "COART" France study. (2005) (112)
Psoriasis: an epidemiological evaluation of disease burden in 590 patients (2010) (101)
Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. (2004) (93)
The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. (1994) (83)
Effectiveness of a Lumbar Belt in Subacute Low Back Pain: An Open, Multicentric, and Randomized Clinical Study (2009) (79)
Current trends in the use of pharmacoeconomics and outcomes research in europe. (1999) (77)
Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma (2010) (54)
The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom (2002) (53)
Health care reform in France--the birth of state-led managed care. (2004) (39)
Economic evaluation of pharmaceuticals: a European perspective. (1993) (35)
The burden cost of French patients suffering from irritable bowel syndrome (2004) (33)
The burden of age-related macular degeneration: results of a cohort study in two French referral centres. (2003) (30)
Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study. (2007) (30)
Public Health and Budget Impact of Probiotics on Common Respiratory Tract Infections: A Modelling Study (2015) (29)
What criteria for pharmaceuticals reimbursement? (2003) (29)
Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. (2003) (27)
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. (2003) (26)
Travel-Associated Rabies in Pets and Residual Rabies Risk, Western Europe (2016) (26)
Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis (2014) (26)
Second line pharmacological management of paroxysmal and persistent atrial fibrillation in france: a cost analysis. (2000) (25)
Cost‐minimization study comparing Simulect® vs. Thymoglobulin® in renal transplant induction (2004) (24)
Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing? (2013) (24)
The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation (2013) (22)
Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience (2015) (21)
Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France (2003) (21)
Erythropoietin and preoperative autologous blood donation in the prevention of hepatitis C infection:necessity or luxury? (1999) (19)
The Burden of Age-Related Macular Degeneration (2012) (19)
A health economic evaluation of needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cysts (2017) (17)
An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France (1999) (17)
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. (2001) (16)
The Drug Budget Silo Mentality: The French Case (2003) (16)
Efficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysis (2011) (16)
Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 2 Years (2005) (14)
Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom (2005) (14)
Economic Evaluation of Pharmaceuticals (1993) (14)
Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France. (2015) (13)
The drug budget silo mentality: the French case. (2003) (13)
[Cost-effectiveness analysis of captopril treatment after myocardial infarction]. (1994) (12)
The Long-Term Effectiveness of Preventive Strategies for Osteoporosis in Postmenopausal Women: A Modeling Approach (2000) (12)
What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France. (2003) (12)
Hospital Reimbursement Price Cap for Cancer Drugs (2012) (12)
Pharmaceutical economy and the economic assessment of drugs in France. (1997) (11)
[Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach]. (1996) (11)
[The financial impact of maintenance treatment in heroin addictive behavior: the case of Subutex]. (2000) (11)
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years. (2005) (10)
Economic Evaluation of Nimesulide versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain (2001) (9)
Is there a “continental” view of health economics evaluation? (2008) (9)
Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. (2001) (9)
Pharmaceutical economy and the economic assessment of drugs in France (1997) (9)
Diagnosis Related Group Costs in a Regulated Environment (2000) (8)
[A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996]. (2002) (8)
Cost-Minimisation Study of Dorzolamide versus Brinzolamide in the Treatment of Ocular Hypertension and Primary Open-Angle Glaucoma In Four European Countries (2012) (8)
[Adherence to guidelines in CHF therapy in Germany]. (2005) (7)
A comparison of radiopharmaceutical agents used for the diagnosis of pulmonary embolism (2001) (7)
Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model (2008) (6)
Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in? (2005) (6)
Drug pricing and reimbursement in France. Towards a new model? (1996) (6)
How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers (2018) (6)
[Cost of treatment and follow up of breast cancer: a retrospective assessment in a comprehensive cancer centre]. (2002) (5)
PNL13 PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE (2004) (5)
From generic to biosimilar drugs: why take an innovative pace? (2012) (5)
Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures (2012) (5)
[The socio-economics of venous diseases: the findings of a survey of consumers of vasotonic medications in France]. (1993) (4)
[Estimation of health care cost for alcoholism in France: advantages and limitations of two evaluation methods]. (1999) (3)
Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model. (2008) (3)
[Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France]. (2005) (3)
Drug Pricing and Reimbursement in France (2012) (3)
Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program (2011) (2)
Refocusing on R&D model or redefining marketing strategy? Anticipating sustainability for generic pharmaceutical industry (2014) (2)
Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. (2021) (2)
Evaluation of treatment costs with recombinant humangranulocyte colony-stimulating factors in the mobilisationof stem cells (2000) (1)
The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries (2020) (1)
[Clinical practice guideline: medical and nonmedical therapeutic strategies for smoking cessation. Bit of therapeutic practice: management and current practice in smoking cessation]. (2003) (1)
Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden (2009) (1)
[Medical-economic models of benign prostatic hypertrophy]. (1998) (1)
Is there a "continental" view of health economics evaluation? (2009) (1)
[Evaluation of a workplace health promotion program]. (2014) (1)
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. (2005) (1)
Rituximab maintenance therapy (RM) for relapsed/refractory follicular lymphoma (FL): Long-term economic impact in the French setting (2007) (1)
PNM11 IMPACT OF DEEP BRAIN STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN ADVANCED PARKINSONIAN PATIENTS (2003) (1)
Indirect costs of rheumatoid arthritis and their Determinants (2009) (1)
Primary care and avoidable hospitalizations : A comparative analysis between france and the uk (2009) (1)
Is Orphan Designation a Driver of Orphan Drug Pricing (2012) (1)
Does pharmaceutical consumption improve health care Status (2009) (1)
PKU4: COST-MINIMISATION STUDY COMPARING SIMULECT VERSUS THYMOGLOBULINE IN RENAL TRANSPLANT INDUCTION (2001) (1)
PSS39 PSORIASIS: AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS (2009) (1)
To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis (2013) (1)
PHP11 DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS (2009) (1)
PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE (2005) (1)
PSS1 VERTEPORFIN IN NEOVASCULAR AMD: REAL LIFE CONFIRMS CLINICAL TRIALS RESULTS (2009) (0)
CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION (2003) (0)
The Emerging Pardigm in Developed Health Systems- Germany, France, Israel, the Netherlands, the UK, and the USA (2007) (0)
PIN33 THE COST OF ZOSTERAND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE (2007) (0)
PID7: MULTITHERAPIES: TOWARDS COST-SAVING STRATEGIES IN REAL LIFE? (2000) (0)
Moving beyond a drug budget mentality: the french case (2003) (0)
PCV24 THE MAHLER STUDY: DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES (2003) (0)
A Method to Derive an Aggregated Score for Assessing Treatment Efficacy in Seasonal Allergic Conjunctivitis (2002) (0)
Medical ethics on risks of health care (2001) (0)
PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES (2019) (0)
Pharmaceuticals: is there a just price for innovation? (2015) (0)
POS5 MEDICO-ECONOMIC EVALUATION OF VERTEBRAL FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN (2004) (0)
Pharmacoeconomical view-point and health care application (2000) (0)
[Prescription and regulation of the health system]. (1994) (0)
[Medico-economic evaluation of abciximab]. (1999) (0)
PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION (2002) (0)
PCN170 PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS (2009) (0)
A Price Comparison Study of Recent Drugs in EU5, 2008-2012 (2013) (0)
PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK (2009) (0)
CN2: AN ECONOMIC COMPARISON OF OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE (1999) (0)
PCN30 ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS (2006) (0)
PEY10 COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV® (2006) (0)
PMDE5: COST-EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA (2000) (0)
PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD) (2005) (0)
PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE (2003) (0)
[Medical ethics on risks of health care]. (2001) (0)
PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY (2005) (0)
PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION (2005) (0)
Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra) (2008) (0)
PCN135 The Economic Value of Medical Progress, the Case of Cancer in France (1990-2010) (2012) (0)
PES9 COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES (2002) (0)
Collective Profitability of Healthcare (2008) (0)
PIN1 PHARMACEUTICAL MANAGEMENT OF NEWLY HIV + DIAGNOSED PATIENTS: RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT (2003) (0)
PES20 DERIVATION OF SYMPTOMS SCORES AND QOL SCORES FROM CLINICAL DATA IN SEASONAL ALLERGIC CONJUNCTIVITIS (2002) (0)
PHP4 PERSPECTIVE OF THE GENERIC MARKET IN FRANCE: 2004-2008 (2004) (0)
PMS62 INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS (2009) (0)
PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS (2008) (0)
PES15 USING A DISCRIMINANT FUNCTION TO MODEL THE LONG-TERM VISUAL FIELD CONSEQUENCES OF IOP CONTROL:A CASE STUDY BASED ON A TIMOLOL, LATANOPROST AND TRAVOPROST CLINICAL TRIAL (2002) (0)
PMS87 IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME (2009) (0)
The MAHLER study: Validation of guidelines for the treatment of congestive heart failure (CHF) in Europe (2003) (0)
PIN9 A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING (2007) (0)
PAR4 THE COART STUDY: THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002 (2004) (0)
“Patient” or “Sick Person”? (2009) (0)
OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES) (2006) (0)
Cost-effectiveness of etanercept and efalizumab In the management of moderate and severe plaque psoriasis (2008) (0)
The cost of zoster and postherpetic neuralgia treatment in France (2007) (0)
Generic pharmaceutical industry: building up an innovative identity (2013) (0)
[The conventional system]. (2014) (0)
424 Confocal Laser Endomicroscopy (CLE): A Dominant Strategy for the Management of Barrett's Esophagus (2015) (0)
CE4 COST-EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH ADVANCED AND/OR METASTATIC BREAST CANCER IN FRANCE (2003) (0)
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVER (2018) (0)
Pharmaceuticals: is there a just price for innovation? (2015) (0)
HP5 WHAT HAPPENS WHEN A PHARMACEUTICAL PRODUCT IS REMOVED OUT OF REIMBURSEMENT (2004) (0)
PCV38: A COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORTRANDOLAPRIL IN THE TREATMENT OF POST INFARCTION IN THE US (2003) (0)
T06.01.19 THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES (2020) (0)
A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets (2014) (0)
PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA) (2008) (0)
EC4 COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING (2007) (0)
PAR5 MESSAGE: AN OBSERVATIONAL POST-LAUNCH STUDYTO ASSESS EFFECTIVENESS AND COST OF SUPLASYN® IN PATIENTS WITH KNEE OSTEOARTHRITIS (2004) (0)
Sources of bias in the economic analysis of new drugs. (2000) (0)

This paper list is powered by the following services:

Other Resources About Claude Le Pen

en.wikipedia.org

What Schools Are Affiliated With Claude Le Pen?

Claude Le Pen is affiliated with the following schools: